Considerable interest has been shown in the measurement of circulating immune complexes in patients with malignant disease as a possible approach to immunodiagnosis or prognosis.'14This was originally stimulated by the descript-ion of faetors in the serum of tumour-bearing patients and animals which interfere with cell-mediated immunity.5 It has also been suggested that circulating or cell-,bound immune complexes may be responsible for the relatively high frequency of serum antiglobulin responses in cancer patients,6 7 and signs and symptoms of so-called "immune complex disease" may be seen in patients with cancer. 9 More recently it has been suggested that immune complexes cause synthesis and release of prostaglandins and release of lysosomal acid hydrolysases from macrophages. 10 Various 24 (75%) in patients with disseminated disease. In both these studies, the control populaltions were healthy blood donors, and the upper normal limit was taken as 4 0 and 4-7% Clq binding respectively. This is considerably lower than the base line levels established in this study using the modified Clq assay with appropriately age-matched controls (mean 7-3+5.0%) and also with the normal value established in the laboratory with healthy donors (6±1+2.5%). In this respect, it is pertinent that there was no significant difference in the serum Clq binding levels of the young healthy control population and the age-matched controls with the lung cancer patients, this group comprising inpatients with benign conditions. From these considerations it is clear that the lower prevalence of elevated Clq binding sera in the lung cancer patients reported here is to some extent the result of the control baseline. This is further emphasised by the observeid mean Clq biniding value in our lung cancer patients (1 15+4 11*8%) when compared to that reported by Rosen et all" (13- 
